On October 20, 2026, OpenAI announced it had acquired Orchestra Bio , a San Francisco platform that uses AI agents to help biopharma teams coordinate the famously messy process of drug development. Orchestra's team and technology fold into Rosalind , OpenAI's life-sciences suite. Terms were not disclosed.

OpenAI shared the deal exclusively with Axios , and it is the latest sign that frontier labs treat life sciences as a core market, not a demo domain. About six months earlier, Anthropic bought Coefficient Bio in a deal reported at roughly $400 million . Both labs are pushing past coding, chat and cybersecurity into the decade-long, high-stakes work of getting new medicines to patients.

What Orchestra Bio Built

Orchestra Bio built an agentic operating layer for drug programs. Rather than design molecules or pick targets, it went after the operational complexity between a scientific insight and an approved treatment.…